Neoplasia/BPH

	Transcriptome-wide association study of prostate cancer in the Chinese population. Asian J Urol Hu W, Zeng X, Zhang J, Ruan X, Zhan Y, Yao C, Xin X, Chen H, Na R. PMID: 42238340 [PubMed]
	Development and validation of prostate-specific membrane antigen-adjusted Prostate Imaging Reporting and Data System: A new approach to enhancing the accuracy of diagnosing treatment-naÃ¯ve primary prostate cancer. Asian J Urol Li X, Song J, Yao X, Zhao Z, Zhang Q, Li R, Zhang P, Wu W, Sun H, Ai S, Yang F, Guo H, Shi K, Afshar-Oromieh A, Zhang L, Lu G, Civelek AC, Wang F. PMID: 42238338 [PubMed]
	Artificial Intelligence as a Diagnostic Tool for Benign Prostatic Hyperplasia (BPH): A Narrative Review. Res Rep Urol Aljazei E. PMID: 42237984 [PubMed]
	A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes. Future Oncol Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Kalac M, Laird AD, Kennedy D, Agarwal N. PMID: 42237765 [PubMed - as supplied by publisher]
	Machine Learning-Integrated Raman Spectroscopy Identifies Race-Associated Biochemical Signatures in Prostate Cancer. J Biophotonics Iftesum M, Sahoo GR, Sheikh E, Srivastava M, Roy S, Shukla HD, Biswal NC, Gartia MR. PMID: 42237462 [PubMed - in process]
	Cytoreductive nephrectomy improves survival in metastatic papillary renal cell carcinoma: a population-based study with machine learning validation and landmark analysis. World J Urol Yuan R, Wang Z, Wu F, Li Z, He Y, Guo Q, Huang W, Xu S. PMID: 42236580 [PubMed - in process]
	Survival Outcomes of a Smoking Cessation Treatment Program After Diagnosis of Bladder Cancer. Eur Urol Oncol MacDonald LP, Kypriotakis G, Karam-Hage M, Minnix JA, Beneventi D, Cui Y, Blalock JA, Robinson JD, Alhalabi O, Hassanazadeh CJ, Lee BH, Navai N, Kamat AM, Dinney CP, Cinciripini PM, Bree KK. PMID: 42236415 [PubMed - as supplied by publisher]
	Re: Khan S, Papa N, Kneebone A, et al. Prospective Comparison of (64)Copper [(64)Cu]SAR-bisPSMA vs (68)Gallium[(68)Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.001. Eur Urol Ding G, Wang J, Wu J. PMID: 42236390 [PubMed - as supplied by publisher]
	Integration of PSMA PET into the New Recommendations from Prostate Cancer Working Group 4 for Prostate Cancer Trials. J Nucl Med Technol Kuo PH, Morris MJ. PMID: 42235999 [PubMed - in process]
	Prostate cancer: All black men aged 45-74 will be offered screening in major trial expansion. BMJ Iacobucci G. PMID: 42235994 [PubMed - in process]
	Electrochemical biosensor-based strategies for sensitive detection of prostate cancer biomarkers. Clin Chim Acta Saha A, Sharma K. PMID: 42235733 [PubMed - as supplied by publisher]
	Diagnostic Delay Duration and Determinants in Hereditary Leiomyomatosis and Renal Cell Cancer: An Observational Study. J Am Acad Dermatol Udupa M, Bendayan E, Allen-Flanagan T, Gunyon M, Alamari A, Ouchene L, Marino TC, Kaouache M, Rahme E, Foulkes WD, Netchiporouk E. PMID: 42235607 [PubMed - as supplied by publisher]
	Explainable artificial intelligence in prostate cancer treatment recommendation: A decision support system for oncological expert panels. Eur J Cancer Duwe G, Mercier D, Kauth V, Jost LM, Moench K, Rajashekar V, Junker M, Neumann CCM, Dengel A, Haferkamp A, Höfner T. PMID: 42235465 [PubMed - as supplied by publisher]
	Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. Eur J Cancer Ahrens M, Haanen J, Albiges L, Goupil MG, Boleti E, Gravis G, Fléchon A, Grimm MO, Bedke J, Barthélémy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Flörcken A, Suárez C, Maroto JP, Grünwald V, Oosting S, Kopecky J, Zschäbitz S, Boegemann M, Buchler T, Niegisch G, Goebell PJ, Waddell T, Joly F, Priou F, Retz M, Siemer S, Zimmermann U, Deckbar D, Burkholder I, Hartmann A, Bergmann L, Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN). PMID: 42235464 [PubMed - as supplied by publisher]
	Evolution of PSMA-GRPr heterobivalent radiolabeled conjugates for the diagnosis and therapy of prostate cancer. Eur J Med Chem Grigoriev GP, Beloglazkina EK, Petrov SA. PMID: 42235186 [PubMed - as supplied by publisher]
	Collecting electronic patient-reported outcomes via smartphone text messages in a bladder cancer RCT: A feasibility study. Urol Oncol Munk L, Kumarasegaram V, Hyldgaard JM, Jensen JB, Graugaard-Jensen C, Lindgren MS. PMID: 42235120 [PubMed - as supplied by publisher]
	Effects of exercise on sexual activity and sexual dysfunction in patients with prostate cancer: a systematic review and meta-analysis. J Sex Med Wen Z, Ding F, Ma X, Zhu Y. PMID: 42234465 [PubMed - in process]
	Spectral CT in renal cell carcinoma: the promising role of dual-energy and photon-counting techniques. Abdom Radiol (NY) Kekelidze M, García-Figueiras R, Kolmos M, Silberbrandt AR, Olech WE, Borgbjerg J, , Flohr T, Alkadhi H, Mirón Mombiela R. PMID: 42234111 [PubMed - as supplied by publisher]
	Toxicity and risk after using new modalities of radiotherapy in Algeria: retrospective intercomparison study. Radiat Prot Dosimetry Boughalia A, Fellah M, El Ghribi Z, Oukrif S. PMID: 42233309 [PubMed - indexed for MEDLINE]
	Ferroptosis and prostate cancer: A translational path from molecular mechanisms to precision therapy. Genes Dis Huang Y, Ma Y, He J, Song T. PMID: 42233093 [PubMed]

Articles 1 - 20 / 188335

Page 1 of 9417



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy